HealthQuill Non-small Cell Lung Cancer
The US Food and Drug Administration (FDA) has granted an accelerated approval for AbbVie Inc.’s drug to treat a specific group of adult lung cancer patients who have tried other systemic treatments.
Drugs Health Pharma

AbbVie’s NSCLC lung cancer drug gets accelerated approval from FDA

 HQ Team May 15, 2025: The US Food and Drug Administration (FDA) has granted an accelerated approval for AbbVie Inc.’s drug to treat.

Read More
AstraZeneca’s combination drug for the treatment of adults with resectable non-small cell lung cancer has got approval from the European Union.
Drugs Health Pharma

AstraZeneca’s lung cancer drug combination gets EU approval 

HQ Team April 4, 2025: AstraZeneca’s combination drug for the treatment of adults with resectable non-small cell lung cancer has got approval from.

Read More
AstraZeneca’s drug for treating limited-stage small cell lung cancer got a recommendation for approval from an EU regulator panel, according to the British-Swedish drugmaker.
Uncategorized

EU panel gives a positive opinion for AstraZeneca’s cancer drug

AstraZeneca’s drug for treating limited-stage small cell lung cancer got a recommendation for approval from an EU regulator panel, according to the British-Swedish.

Read More
The US regulator has granted a breakthrough therapy designation to British-Swedish AstraZeneca and Japan’s Daiichi Sankyo experimental drug for treating a certain type of lung cancer.
Drugs Medical Pharma

AstraZeneca, Daiichi’s trial drug for lung cancer, gets US regulator’s nod

The US regulator has granted a breakthrough therapy designation to British-Swedish AstraZeneca and Japan’s Daiichi Sankyo experimental drug for treating a certain type.

Read More
Gilead Sciences, Inc. has withdrawn its bladder cancer drug from the US market and stopped its confirmatory clinical trial after it failed to extend the lives of patients who had undergone prior treatments.
Drugs Health Pharma

Gilead’s end-stage confirmatory trials of bladder cancer drug fail

Gilead Sciences, Inc. has withdrawn its bladder cancer drug from the US market and stopped its confirmatory clinical trial after it failed to.

Read More
Daiichi Sankyo and Merck & Co., Inc. will initiate talks with global regulatory agencies after an end-stage trial of its drug for a form of lung cancer improved patients’ chances of extending survival without the disease progressing.
Drugs Health Pharma

Daiichi Sankyo-Merck’s trial lung cancer drug meets primary goal

Daiichi Sankyo and Merck & Co., Inc. will initiate talks with global regulatory agencies after an end-stage trial of its drug for a.

Read More
Summit Therapeutics Inc.’s investigational drug ivonescimab helps lung cancer patients to cut the risk of progression or death from the disease by 48%, the latest results of the company's trials reveal.
Drugs Health Pharma

Summit’s lung cancer drug reduces risk of disease progression by 48%

Summit Therapeutics Inc.’s investigational drug ivonescimab helps lung cancer patients to cut the risk of progression or death from the disease by 48%,.

Read More
The US Federal Drug Administration approved Illumina Inc.’s DNA sequencing cancer tests that check more than 500 genes in a tumour to help find targeted therapy options.
Drugs Health Pharma

Illumina’s DNA sequencing cancer tests to check 500 genes get US nod

The US Federal Drug Administration approved Illumina Inc.’s DNA sequencing cancer tests that check more than 500 genes in a tumour to help.

Read More
https://investor.g1therapeutics.com/news-releases/news-release-details/fda-approves-g1-therapeutics-coselatm-trilaciclib-first-and-only
Drugs Health Pharma

Denmark’s Pharmacosmos to buy G1 Therapeutics for $405 million

Danish biotechnology company, Pharmacosmos A/S will buy US-based G1 Therapeutics Inc., for $405 million to expand its global commercial portfolio in haematology.

Read More
The USFDA has rejected a Biologics License Application from Daiichi Sankyo and Merck & Co., seeking accelerated approval of patritumab deruxtecan to treat a type of lung cancer.
Drugs Health Pharma

FDA rejects Daiichi, Merck, antibody-drug conjugate application

The USFDA has rejected a Biologics License Application from Daiichi Sankyo and Merck & Co., seeking accelerated approval of patritumab deruxtecan to treat.

Read More